|
Agitation in Alzheimer's Disease Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Agitation in Alzheimer's Disease conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Agitation in Alzheimer's Disease Clinical research trials and Agitation in Alzheimer's Disease health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Agitation in Alzheimer's Disease. Agitation in Alzheimer's Disease Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Agitation in Alzheimer's Disease clinical trial. Participants oftentimes recieve the most expert healthcare available for their Agitation in Alzheimer's Disease condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Agitation in Alzheimer's Disease  Agitation in Alzheimer's Disease
Agitation in Alzheimer's Disease
For Condition: Alzheimer Disease
Status: Completed
Sponsor(s): National Institute on Aging (NIA) ,
Synopsis: Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs for agitation in AD patients. Behavior management, a non drug approach, has been effective in reducing signs of agitation. Researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in AD patients and determine which is the best treatment. The Alzheimer's Disease Cooperative Study, with funding from the National Institute on Aging, is conducting an agitation treatment program at 21 sites in 16 States. This study will assess which of the above treatments is most effective.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: 50 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Memory problem consistent with a probable diagnosis of Alzheimer's disease (AD) - Agitation symptoms for at least the past 2 weeks - Patient has caregiver who can participate - Patient lives in the same household as the caregiver
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LeonThal, Principal Investigator, University of California, San Diego
University of Miami
Miami, Florida, 33140
United States
University Hospitals of Cleveland
Cleveland, Ohio, 44120
United States
University of Rochester
Rochester, New York, 14620
United States
University of Michigan
Ann Arbor, Michigan, 48109
United States
Oregon Health Sciences University
Portland, Oregon, 97201-3098
United States
Southern Illinois University
Springfield, Illinois, 62702
United States
Mount Sinai Medical Center
New York City, New York, 10029
United States
University of California, Los Angeles
Los Angeles, California, 90095
United States
New York University Medical Center
New York City, New York, 10016
United States
University of South Florida
Tampa, Florida, 33162
United States
University of Kansas Medical Center
Kansas City, Kansas, 66160
United States
University of Minnesota
Minneapolis, Minnesota, 55455
United States
University of Massachusetts
Worcester, Massachusetts, 01665
United States
University of California, San Diego
San Diego, California, 92093-0949
United States
University of Kentucky
Lexington, Kentucky, 40536
United States
Emory University
Atlanta, Georgia, 30329
United States
Additional Information:
Study ID Numbers: IA0003; 3U01AG10483-08S2
Study Start Date:
Record last reviewed: November 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000179
Other Alzheimer Disease Studies:
1. Evaluation Of Three Doses of NS 2330 in Patients with Mild to Moderate Dementia of the Alzheimer’s Type
2. Estrogen Protocol
3. Alzheimer's Disease: Therapeutic Potential of Estrogen
4. Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study
5. Vitamin E in Aging Persons With Down Syndrome
Related Studies:
Other Alzheimer Disease Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Agitation in Alzheimer's Disease
|
|
|
|
|
|
|
|
